Maveropepimut-S (MVP-S)
Recurrent Ovarian Cancer
Key Facts
About BioVaxys
BioVaxys is a clinical-stage biopharma company focused on harnessing the immune system to combat cancer and infectious diseases. Its strategic acquisition of IMV Inc. transformed the company, providing a validated DPX™ delivery platform and mid-stage clinical assets, most notably the Phase 2B cancer vaccine maveropepimut-S (MVP-S). The company's business model centers on advancing its platform and pipeline to proof-of-concept before out-licensing to larger partners for late-stage development and commercialization.
View full company profileAbout BioVaxys
BioVaxys is a clinical-stage biopharma company focused on harnessing the immune system to combat cancer and infectious diseases. Its strategic acquisition of IMV Inc. transformed the company, providing a validated DPX™ delivery platform and mid-stage clinical assets, most notably the Phase 2B cancer vaccine maveropepimut-S (MVP-S). The company's business model centers on advancing its platform and pipeline to proof-of-concept before out-licensing to larger partners for late-stage development and commercialization.
View full company profileAbout BioVaxys
BioVaxys is a clinical-stage biopharma company focused on harnessing the immune system to combat cancer and infectious diseases. Its strategic acquisition of IMV Inc. transformed the company, providing a validated DPX™ delivery platform and mid-stage clinical assets, most notably the Phase 2B cancer vaccine maveropepimut-S (MVP-S). The company's business model centers on advancing its platform and pipeline to proof-of-concept before out-licensing to larger partners for late-stage development and commercialization.
View full company profileAbout BioVaxys
BioVaxys is a clinical-stage biopharma company focused on harnessing the immune system to combat cancer and infectious diseases. Its strategic acquisition of IMV Inc. transformed the company, providing a validated DPX™ delivery platform and mid-stage clinical assets, most notably the Phase 2B cancer vaccine maveropepimut-S (MVP-S). The company's business model centers on advancing its platform and pipeline to proof-of-concept before out-licensing to larger partners for late-stage development and commercialization.
View full company profileTherapeutic Areas
Other Recurrent Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ovarian Cancer CER-T | Anixa Biosciences | Phase 1 |